NEW YORK, NY / ACCESS Newswire / July 31, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=159154&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or […]

MDL bellwether cases are the first to address the largest data breach in 2023. BOSTON, MA / ACCESS Newswire / July 31, 2025 / Today, a Massachusetts federal court largely denied the motions to dismiss in two bellwether cases against Progress Software Corporation and other defendants in In Re: MOVEit Customer Data Security Breach Litigation–

NEW YORK, NY / ACCESS Newswire / July 31, 2025 / If you suffered a loss on your Centene Corporation (NYSE:CNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/centene-corporation-lawsuit-submission-form?prid=159155&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Pomerantz LLP is investigating claims on behalf of investors ofDuolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherDuolingo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining

Pomerantz LLP is investigating claims on behalf of investors ofMolina Healthcare, Inc. (“Molina” or the “Company”)(NYSE: MOH).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherMolina and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining

Pomerantz LLP is investigating claims on behalf of investors ofCharter Communications, Inc. (“Charter” or the “Company”)(NASDAQ: CHTR).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherCharter and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining

Pomerantz LLP is investigating claims on behalf of investors ofExelixis, Inc. (“Exelixis” or the “Company”)(NASDAQ: EXEL).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherExelixis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the

Pomerantz LLP is investigating claims on behalf of investors ofNeoGenomics, Inc. (“NeoGenomics” or the “Company”)(NASDAQ: NEO).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherNeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the

Pomerantz LLP is investigating claims on behalf of investors ofAnika Therapeutics, Inc. (“Anika” or the “Company”)(NASDAQ: ANIK).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherAnika and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining

Pomerantz LLP is investigating claims on behalf of investors ofNovo Nordisk A/S (“Novo Nordisk” or the “Company”)(NYSE: NVO).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whetherNovo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information